Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank

J Am Coll Cardiol. 2007 Jul 3;50(1):40-7. doi: 10.1016/j.jacc.2007.02.067. Epub 2007 Jun 18.

Abstract

Objectives: The goal of this study was to identify potentially novel laboratory markers of risk in chronic heart failure patients.

Background: Although a variety of prognostic markers have been described in heart failure, a systematic assessment of routine laboratory values has not been reported.

Methods: All 2,679 symptomatic chronic heart failure patients from the North American CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program had a wide range of laboratory measures performed at a core facility, enabling us to assess the relationship between routine blood tests and outcomes using a Cox proportional hazards model. We then replicated our findings in a cohort of 2,140 heart failure patients from the Duke Databank.

Results: Among 36 laboratory values considered in the CHARM program, higher red cell distribution width (RDW) showed the greatest association with morbidity and mortality (adjusted hazard ratio 1.17 per 1-SD increase, p < 0.001). Higher RDW was among the most powerful overall predictors, with only age and cardiomegaly showing a better independent association with outcome. This finding was replicated in the Duke Databank, in which higher RDW was strongly associated with all-cause mortality (adjusted hazard ratio 1.29 per 1 SD, p < 0.001), second only to age as a predictor of outcome.

Conclusions: In 2 large contemporary heart failure populations, RDW was found to be a very strong independent predictor of morbidity and mortality. Understanding how and why this marker is associated with outcome may provide novel insights into heart failure pathophysiology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Benzimidazoles / therapeutic use*
  • Biomarkers / blood
  • Biphenyl Compounds
  • Cause of Death*
  • Cohort Studies
  • Databases as Topic
  • Disease Progression
  • Erythrocytes / cytology*
  • Female
  • Heart Failure / diagnosis
  • Heart Failure / drug therapy*
  • Heart Failure / mortality*
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Probability
  • Prognosis
  • Proportional Hazards Models
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Survival Analysis
  • Tetrazoles / therapeutic use*

Substances

  • Benzimidazoles
  • Biomarkers
  • Biphenyl Compounds
  • Tetrazoles
  • candesartan